Once a health care intervention (pharmaceutical/medical device/vaccine) has gained regulatory approval, thereby showing its efficacy and safety, a decision must be made by payers on whether to reimburse its use. The health care environment is facing increasing financial strain, for example with aging populations. Alongside this, innovative new treatments are being developed that put pressure on established models of reimbursement. Health technology assessment (HTA) agencies aim to provide insight to drive the decision-making process of the reimbursement decision maker, and this channel focuses on topics relevant to the HTA process.
Interested in health technology assessment? Read more content from The Journal of Comparative Effectiveness Research>>